Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2026-02-08 @ 8:59 PM
Study NCT ID:
NCT03821935
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-25
First Post:
2019-01-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor:
AbbVie
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Solid Tumors Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Advanced Solid Tumors Cancer | View |
| None | cancer | View |
| None | Solid Tumors | View |
| None | metastatic | View |
| None | monotherapy | View |
| None | combination therapy | View |
| None | triple negative breast cancer (TNBC) | View |
| None | pancreatic adenocarcinoma | View |
| None | urothelial cancer | View |
| None | hepatocellular carcinoma (HCC) | View |
| None | head and neck squamous cell carcinoma (HNSCC) | View |
| None | Colorectal cancer | View |
| None | Ovarian granulosa cell tumors | View |